Vytorin Beats Lipitor At LDL-Lowering In Data Analysis
This article was originally published in The Pink Sheet Daily
Executive Summary
A Merck/Schering-Plough-sponsored data analysis presented at the American College of Cardiology Scientific Sessions March 13 showed that more patients treated with Vytorin (ezetimibe/simvastatin) achieved lower levels of LDL cholesterol and apolipoprotein B compared to patients taking Pfizer's Lipitor (atorvastatin)